Anurag Shrivastava, MD
Glaucoma Specialist · Palo Alto, CANPI 1760518823
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (52.9%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. AbbVie accounts for 85.2% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2019 at $22,591 and has fallen 98.7% since, to $305 in 2025.
Across 52 payments — averaging $465.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$21K
- Alcon$3K
- Aerie Pharmaceuticals, Inc.$444
- Sight Sciences, Inc.$128
- Johnson & Johnson Surgical Vision, Inc.$99
- Ivantis, Inc$79
- plus $20 from 1 others
Across 43 payments — averaging $1806.73 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$78K
What the payments were for
- Consulting fees$12,78553%
- Travel & lodging$8,59336%
- Food & beverage$2,80412%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 30 | $20,607 |
| Alcon | 11 | $2,804 |
| Aerie Pharmaceuticals, Inc. | 4 | $444 |
| Sight Sciences, Inc. | 3 | $128 |
| Johnson & Johnson Surgical Vision, Inc. | 2 | $99 |
| Ivantis, Inc | 1 | $79 |
| Sun Pharmaceutical Industries Inc. | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$24,181 in reported general payments places this provider in the 75th percentile of 64 glaucoma specialist providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 159 | $100,890 |
| LumiganBimatoprost | 139 | $62,885 |
| XiidraLifitegrast | 37 | $29,724 |
| CombiganBrimonidine Tartrate/Timolol | 41 | $19,975 |
| Cyclosporine | 47 | $18,394 |
| RhopressaNetarsudil Mesylate | 42 | $14,331 |
| RocklatanNetarsudil Mesylat/Latanoprost | 27 | $10,696 |
| Latanoprost | 643 | $5,303 |
| Azelastine Hcl | 380 | $4,913 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 13 | $4,818 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 209 | $3,217 |
| Brimonidine Tartrate | 151 | $2,413 |
| Prednisolone Acetate | 36 | $1,437 |
| Dorzolamide Hcl | 66 | $1,077 |
| Pilocarpine Hcl | 13 | $701 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan | $20,607 | $183,750339 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan | $444 | $25,02769 claims |
| AlconSimbrinza | $2,804 | $4,81813 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 64 glaucoma specialist providers in California.
Other glaucoma specialist in Palo Alto
- Jason BacharachPetaluma$1.7M
- Billy PanBeverly Hills$250K
- Jacob BrubakerSacramento$229K
- Felise May BarteSanta Clara$121K
- Houman VosoghiWestlake Village$119K
- Robert ChangStanford$105K
- Sophia WangStanford$77K
- Jeffrey GoldbergStanford$57K
- Valentina LozanoCulver City$51K
- Sameh MosaedIrvine$44K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.